

## ORIGINAL ARTICLE

# Urinary prostaticin in humans: relationships among prostaticin, aldosterone and epithelial sodium channel activity

Aya Koda<sup>1</sup>, Naoki Wakida<sup>2</sup>, Kazuhiro Toriyama<sup>1</sup>, Kazutoshi Yamamoto<sup>3</sup>, Hiromi Iijima<sup>4</sup>, Kimio Tomita<sup>2</sup> and Kenichiro Kitamura<sup>2</sup>

Prostaticin, a membrane-bound serine protease, is known to increase the activity of the epithelial sodium channel (ENaC). Gene expression of prostaticin was shown to be regulated by aldosterone, which increases the rate of sodium reabsorption through ENaC. To clarify the physiological relationships among prostaticin, aldosterone and ENaC, we developed a specific radioimmunoassay (RIA) for human prostaticin. Prostaticin levels in urine were determined in 26 normotensive and 121 hypertensive subjects. Aldosterone content in urine and plasma, urinary Na/K ratio and other clinical parameters were also measured. We observed a highly significant correlation between prostaticin and aldosterone concentration in urine (correlation coefficient: 0.673,  $P < 0.0001$ ). A significant correlation was also found between urinary prostaticin and plasma aldosterone concentration (correlation coefficient: 0.229,  $P < 0.05$ ). In addition, urinary prostaticin excretion was inversely correlated with urinary Na/K ratio (correlation coefficient:  $-0.425$ ,  $P < 0.0001$ ). In conclusion, we developed a prostaticin-specific RIA and applied it to the clinical study. Our findings suggest that urinary prostaticin level is strongly correlated with urinary or plasma aldosterone level and may serve as a surrogate marker for ENaC activation in hypertensive patients. However, it is not clear, at the present time, whether endogenous aldosterone regulates prostaticin expression or vice versa.

*Hypertension Research* (2009) 32, 276–281; doi:10.1038/hr.2009.6; published online 27 February 2009

**Keywords:** aldosterone; epithelial sodium channel; prostaticin

## INTRODUCTION

Aldosterone, a principal human mineralocorticoid hormone, is well known as the primary hormone that regulates salt balance, extracellular fluid volume and blood pressure (BP).<sup>1–3</sup> It has also been reported that aldosterone enhances the rate of sodium reabsorption across epithelial cells of the distal nephron by increasing sodium transport through the epithelial sodium channel (ENaC), a principal physiological target of aldosterone,<sup>4,5</sup> consisting of three homologous subunits ( $\alpha$ ,  $\beta$  and  $\gamma$ ).<sup>6,7</sup>

In 1997, Vallet *et al.*<sup>8</sup> identified a novel mechanism for the local regulation of ENaC activity. They cloned a trypsin family serine protease, xCAP1 (channel-activating protease 1), from a *Xenopus* kidney epithelial cell line (A6), by using a functional complementation assay designed to detect activators of ENaC in the *Xenopus* oocyte expression system. In this assay, they showed a two- to threefold activation of ENaC when xCAP1 was coexpressed with rat or *Xenopus* ENaC in oocytes. This effect is thought to rely on extracellular xCAP1 protease activity, as exposure of the apical membrane to the protease inhibitor aprotinin reduced amiloride-sensitive sodium transport. The first mammalian homologue of xCAP1, mouse CAP1 (mCAP1), was

isolated from a mouse cortical collecting duct cell line.<sup>9</sup> Vuagniaux *et al.*<sup>9</sup> suggested that CAP1 is an orthologous gene for prostaticin, and also showed that mCAP1 increases amiloride-sensitive sodium currents when coexpressed with ENaC in *Xenopus* oocytes.

Prostaticin, a serine protease originally purified from human seminal fluid,<sup>10–12</sup> is synthesized with a glycosylphosphatidylinositol membrane anchor and can also be secreted into physiological fluids.<sup>13</sup> This protein is abundantly present in the seminal fluid, urine and prostate gland, and it is also present at moderate levels in the kidney, bladder, lung, colon, pancreas, salivary gland, bronchi, liver and endometrium.<sup>10,11,14–16</sup> Prostaticin has been identified as a potential regulator of amiloride-sensitive ENaC function in the kidney, lung and airways.<sup>17–23</sup> However, the physiological role of this protein remains largely undetermined, although dysregulation of prostaticin expression has been found in high-grade human prostate and breast cancers.<sup>14,24–26</sup> Catalytically active prostaticin was detected in urine from both men and women.<sup>10</sup> Although the concentration of prostaticin in urine is lower than that in seminal fluid, the production of prostaticin has to be very active in the kidney, considering the relatively large amount of the urine excreted in a day. These facts suggest the possibility that

<sup>1</sup>Hypertension Research Unit, Novartis Institute for BioMedical Research, Tsukuba, Ibaraki, Japan; <sup>2</sup>Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan; <sup>3</sup>Department of Biology, School of Education, Waseda University, Nishi-waseda, Tokyo, Japan and <sup>4</sup>Hitachi Chemical Co. Ltd, Hitachi, Ibaraki, Japan  
Correspondence: Dr K Kitamura, Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, Kumamoto 860-8556, Japan.  
E-mail: ken@gpo.kumamoto-u.ac.jp

Received 1 April 2008; revised 12 December 2008; accepted 16 January 2009; published online 27 February 2009

prostaticin may play a key role in the regulation of renal tubular sodium transport by an autocrine and/or paracrine mechanism.

Recently, we also showed that rat CAP1/prostaticin activates ENaC when the two are coexpressed in *Xenopus* oocytes, and that aldosterone substantially increases prostaticin expression with functional consequences on sodium balance *in vivo*.<sup>27</sup> Furthermore, we showed that urinary excretion of prostaticin in patients with primary aldosteronism was substantially elevated and normalized after adrenalectomy.<sup>19</sup> Regarding urinary prostaticin, Olivieri *et al.*<sup>20</sup> showed that spironolactone increased the urinary Na/K ratio and decreased urinary prostaticin level in normotensives in whom the renin-aldosterone axis was activated by a low sodium intake, suggesting the regulation of urinary prostaticin by aldosterone. On the contrary, however, one report presented evidence that the expression of prostaticin by adenovirus-mediated human prostaticin gene delivery resulted in a subsequent increase in aldosterone production and hypertension in rats.<sup>28</sup> BP increase was accompanied by elevated plasma aldosterone after prostaticin gene transfer, before the development of hypertension, indicating that stimulation of aldosterone production is the primary target of prostaticin. Accordingly, it is unclear whether aldosterone increases prostaticin expression or, on the contrary, if preceding stimulation of prostaticin leads to the release of aldosterone from adrenal gland. To determine the role of prostaticin in the pathophysiology of hypertension or hyperaldosteronism, it is important to develop a prostaticin-specific and high-sensitive assay method. Therefore, in this article, we describe the development of a specific radioimmunoassay (RIA) for human prostaticin and its application to the evaluation of prostaticin levels in urine from normotensive and hypertensive subjects. The physiological relationships among prostaticin, BP, aldosterone and ENaC function were analyzed and discussed.

## METHODS

### Purification of recombinant human prostaticin

A cDNA for recombinant human prostaticin was created by inserting an enterokinase cleavage site, Asp-Asp-Asp-Asp-Lys, between the light chain and heavy chain and by replacing the C-terminal membrane anchoring domain with a 6× His tag, so that the recombinant protein could be secreted as a proprotein and could be activated by exogenous enterokinase treatment. The cDNA was subcloned into the transfer vector pM00001 (Katakura Industries, Saitama, Japan). Linearized hybrid baculovirus DNA 'Bac-Duo' (Katakura Industries) was co-transfected with the recombinant plasmid into a *Spodoptera frugiperda* cell line SF21AE. Three days after transfection, the culture supernatants containing recombinant human prostaticin virus were harvested and subjected to the standard plaque purification methods. Silkworm larvae at the early stage of the fifth-instar were infected with  $9 \times 10^4$  plaque-forming units (PFU) of recombinant virus. On the fifth day after infection, hemolymph containing recombinant human prostaticin was harvested by cutting off several abdominal legs from each larva. The hemolymph was collected in 0.1 M phosphate buffer (PB), pH 6.8 supplemented with 0.1% N-phenylthiourea. Recombinant human prostaticin was purified using a Ni-sepharose column (HisTrap HP; GE Healthcare Bio-Sciences, Piscataway, NJ, USA) and an ion-exchange column (Resource Q; GE Healthcare Bio-Sciences) with an AKTA prime system (GE Healthcare Bio-Sciences). Purified recombinant prostaticin was incubated with enterokinase (EK Max; Invitrogen, Carlsbad, CA, USA) for 16 h at 37 °C to generate an enzymatically active recombinant human prostaticin by cleaving the enterokinase cleavage site between the light and heavy chains. Sixteen hours after incubation, enterokinase was removed from the reaction mixture by using an enterokinase removal kit (Sigma, St Louis, MO, USA). Enzymatic activity of prostaticin was assessed by an assay using a synthetic substrate, N-t-Boc-Gln-Ala-Arg-7-amido-4-methyl coumarin (QAR-MCA). Application of the active recombinant prostaticin significantly increased the ENaC activity in *Xenopus* oocytes, indicating the reliability of this recombinant protein (data not shown).

### Production of antiserum

For antibody production, a partial sequence of peptide<sub>(102-120)</sub> of human prostaticin, AHQLDSYSEDAKVSTLKDII, was synthesized as an octa-branching multiple antigenic peptide (Peptide Institute, Osaka, Japan) consisting of a core matrix made up of three levels of lysine and eight amino termini for anchoring peptide antigens.<sup>29</sup> Antiserum against a synthetic prostaticin peptide was generated in a rabbit by means of the lymph node injection technique.<sup>30</sup> For immunization, 100 µg of multiple antigenic peptide was dissolved in 100 µl of saline, emulsified with an equal volume of Freund's complete adjuvant (Dibco, Detroit, MI, USA), and injected into the popliteal lymph nodes. Starting 2 weeks after the first injection, four subcutaneous injections (100 µg each) were given at multiple sites on the dorsal surface of the rabbit every 2 weeks. Blood was collected from the marginal ear vein every week, starting after subcutaneous injections had begun, and tested for antibody titer by enzyme-linked immunosorbent assay. Two weeks after the last injection, the rabbit was bled from the carotid artery. The serum was separated by centrifugation and stored at -80 °C. Before use, the antiserum was purified with a synthetic human prostaticin peptide-conjugated affinity column (Affi-Gel; Bio-Rad Laboratories, Hercules, CA, USA), and the obtained antibody solution was neutralized, lyophilized and reconstructed to the volume of starting material with 0.01 M PB. The generated antibody did not show any cross-reactivity with renin, angiotensin-converting enzyme, kallikrein, prostaglandins and steroids (data not shown).

### Radioiodination of human prostaticin peptide

For use as a radioligand, human prostaticin peptide consisting of 19 amino-acid residues was synthesized (Peptide Institute). Radioiodination was carried out at room temperature according to the modified lactoperoxidase method, as described previously.<sup>31</sup> Briefly, Na<sup>125</sup>I (7.4 MBq, carrier free; GE Healthcare Bio-Sciences) in 2 µl of 0.1 N NaOH was added to an eppendorf tube containing 25 µl of 0.5 M PB (pH 6.9), 2.5 µg prostaticin peptide in 10 µl of 0.05 M PB (pH 7.3) and 500 ng lactoperoxidase (Sigma) in 5 µl of distilled water. The reaction was started by adding 10 µl of 0.00025% H<sub>2</sub>O<sub>2</sub>. To maintain the reaction, 10 µl H<sub>2</sub>O<sub>2</sub> was added after 1, 3 and 6 min. After 10 min of reaction, the reaction mixture was applied to a Sephadex G10 (GE Healthcare Bio-Sciences) column (12×0.6 cm) that had been washed with 2 ml of 1% bovine serum albumin (BSA; Sigma) in 0.05 M PB (pH 7.3) and equilibrated with 0.05 M PB (pH 7.3). Four hundred microliter aliquots were collected in tubes containing 200 µl of 1% BSA-PBS (phosphate-buffer saline) (0.01 M PB containing 0.14 M NaCl, 1% BSA and 0.1% NaN<sub>3</sub>, pH 7.5). The radioactivity of each fraction was counted in an Aloka gamma counter (AccuFLEX-γ; Aloka, Tokyo, Japan).

### Radioimmunoassay procedure

In this RIA system, recombinant human prostaticin was used as a reference standard. RIA was performed using a double-antibody method. The prostaticin antiserum diluted 1:1000 exhibited the ability to specifically bind 22% of added radioligand in the absence of any unlabeled recombinant prostaticin, when 100 µl of diluted antiserum and 100 µl of labeled prostaticin peptide (10 000 cpm) were added to each assay tube containing 300 µl of 1% BSA-PBS. This dilution (final dilution 1:5000) was used throughout the experiments. The RIA was carried out in disposable polystyrene tubes (10×50 mm evergreen; Evergreen Scientific, Los Angeles, CA, USA). The reference standard or test sample was serially diluted with the assay buffer (1% BSA-PBS, pH 7.5) and then added to assay tubes containing 200 µl of assay buffer in 100-µl volumes. The antiserum was diluted 1:1000 with 0.05 M EDTA-PBS (pH 7.5) containing 1% normal rabbit serum. One hundred microliters of diluted antibody and 100 µl of labeled prostaticin peptide diluted with assay buffer were added to each tube in a total volume of 500 µl. Each preparation was assayed in duplicate. All assay tubes were incubated for 24 h at room temperature. After incubation, the immune complexes were precipitated by the addition of 200 µl of 1:100 dilution of goat anti-rabbit IgG serum (Shibayagi, Gunma, Japan) in 0.05 M EDTA-PBS containing 3.2% polyethylene glycol 6000. After incubation for 24 h at room temperature, each tube was centrifuged at 4 °C for 30 min at 3500 r.p.m., and the supernatant was aspirated. The radioactivity in each precipitate was counted in a gamma counter (Aloka). The radioactivity in tubes containing antibody and labeled prostaticin peptide but no unlabeled prostaticin was

**Table 1 Patient characteristics**

Age (year)	20–86 (mean: 57.9)
Male/female (n)	66:81
Systolic blood pressure (mm Hg)	138.9 ± 2.3
Diastolic blood pressure (mm Hg)	80.9 ± 1.3
Heart rate (beats min <sup>-1</sup> )	73.5 ± 1.0
Serum creatinine (mg per 100 ml)	1.3 ± 0.1
Serum Na (mequiv. l <sup>-1</sup> )	140.8 ± 0.5
Serum K (mequiv. l <sup>-1</sup> )	4.3 ± 0.1
Serum Cl (mequiv. l <sup>-1</sup> )	106.6 ± 0.3
Plasma aldosterone concentration (pg ml <sup>-1</sup> )	85.3 ± 5.3
Plasma renin activity (ng ml <sup>-1</sup> h <sup>-1</sup> )	2.6 ± 0.4
Plasma cortisol (pg ml <sup>-1</sup> )	12.7 ± 5.6
Urinary Na (mequiv. l <sup>-1</sup> )	106.4 ± 0.5.3
Urinary K (mequiv. l <sup>-1</sup> )	35.1 ± 0.2.7
Urinary Cl (mequiv. l <sup>-1</sup> )	113.2 ± 0.6.6
Urinary aldosterone (ng ml <sup>-1</sup> )	3.9 ± 0.0.6
Urinary albumin (mggCr <sup>-1</sup> )	281.2 ± 832.3

Values are expressed as means ± s.e. (n=147).

designated 100%, and the counts in the other tubes were expressed as a fraction of this value.

### Human subjects


The protocol used in this study was approved by the institutional review board of Kumamoto University, and informed consent was obtained from all subjects. Twenty-six healthy volunteers, who presented BP < 140/90 mm Hg and were not on any therapy, were used as a control. Subjects who were already taking antihypertensive therapy or who exhibited systolic BP and diastolic BP of 140 and 90 mm Hg, respectively, or greater were regarded as hypertensive. Hypertensive subjects with chronic kidney disease (stage 1–4) were also included, and subjects who were taking inhibitors for renin–angiotensin–aldosterone system and diuretics were excluded from our study. As most of the hypertensive subjects were being treated with antihypertensive medication, there were many subjects who exhibited systolic BP/diastolic BP less than 140/90 mm Hg. All subjects were not on salt-restricted diet. Urinary prostaticin concentration was examined in 26 normotensive and 121 hypertensive subjects (20–86 years of age; 66 males and 81 females). Blood samples for aldosterone and cortisol, and urine samples for aldosterone, potassium, sodium, albumin and prostaticin evaluation were also collected at the same time. These clinical parameters were measured commercially (SRL, Tokyo, Japan), and the results are summarized in Table 1.

### Preparation of urine

Urine was collected in the morning and immediately chilled on ice. After measuring each urine volume, the pH was adjusted to 7.0 with 1 N NaOH; then, complete protease inhibitor cocktail (Roche Diagnostics, Tokyo, Japan) was added to inhibit the activity of endogenous proteases present in the urine. Urine was centrifuged at 4 °C for 20 min at 5000 r.p.m., filtrated through a 0.45-µm filter (Millipore, Tokyo, Japan), and concentrated by means of Centricon Plus-20 centrifuge filters (molecular weight cutoff 10 000; Millipore) with the concentration ratio between 1/2 and 1/10. The final volume was accurately measured.

### Western blot analysis

Aliquots of the concentrated urine samples obtained from the human subjects were subjected to SDS-polyacrylamide gel electrophoresis in 10% polyacrylamide gels. After electrophoresis, proteins were transferred electrophoretically to Immobilon PVDF membranes (Millipore). Membranes were immunostained by the peroxidase-antiperoxidase method using a mouse monoclonal antibody against human prostaticin (BD Biosciences, San Jose, CA, USA).



**Figure 1** Representative displacement of <sup>125</sup>I-labeled human prostaticin peptide with serial dilutions of recombinant human prostaticin as a standard, seminal fluid and urine in human. The antiserum against a synthetic prostaticin peptide was used at a final concentration of 1:5000. All points are averages of two determinations.


### Statistical analysis

Statistics for linearity, parallelism, precision and potency estimation in the parallel line assay were computed according to the method of Bliss.<sup>32</sup> Simple correlation coefficients were calculated between urinary prostaticin level and plasma aldosterone or urinary aldosterone and Na/K ratio in hypertensive patients. The statistical significance of the correlation was evaluated by the method of Snedecor and Cochran.<sup>33</sup>


### RESULTS

A specific RIA for human prostaticin was developed by using a synthetic partial peptide of human prostaticin for antibody production and radioligand, and a recombinant prostaticin as a reference standard. The recombinant human prostaticin standard resulted in a log-dose inhibition of binding of <sup>125</sup>I-labeled prostaticin peptide to the antiserum (Figure 1). The sensitivity of the RIA, defined as the amount of recombinant prostaticin that significantly decreased the counts by 2 s.d. from the 100% value, averaged 55.2 ± 11.0 ng (mean of five assays ± s.e.) prostaticin per 100 µl of assay buffer. The precision of the assay was determined by assaying the recombinant prostaticin standard. The interassay coefficient of variation was 8.2% when the estimated dose required for 50% inhibition in five assays was used. The intra-assay coefficient of variation of 1.3% was obtained by repeated determinations using a 1563-ng recombinant prostaticin standard. The linear portions of the inhibition curves obtained using seminal fluid and urine of humans paralleled the linear portion of the inhibition curve obtained with recombinant prostaticin (Figure 1). To confirm the reliability of this RIA system, we compared the amount of prostaticin in urine determined by the RIA with the abundance of prostaticin detected by immunoblotting of the corresponding urine sample. As shown in Figure 2, each immunoassayable prostaticin level (Figure 2a) corresponded to that immunoreacted with a monoclonal antibody against human prostaticin (Figures 2b and c).

The RIA was applied to the determination of urinary prostaticin in 26 normotensive and 121 hypertensive subjects. Urinary or plasma aldosterone levels, and other major clinical characteristics (Table 1),




**Figure 2** Relationship between radioimmunoassay (RIA) and immunoblotting in the determination of urinary prostaticin levels. (a) RIA result, (b) immunoblotting result and (c) intensity of the prostaticin band immunoreacted with prostaticin antibody.




**Figure 3** Correlation between prostaticin and aldosterone levels in urine. Correlation coefficient is 0.673 ( $P<0.0001$ ).

were also evaluated to clarify the physiological relationships among prostaticin, aldosterone and ENaC function. In this study population, the values for urinary prostaticin increased as the concentration of urinary aldosterone excretion increased, showing a high significant correlation (correlation coefficient: 0.673;  $P<0.0001$ ) (Figure 3). As shown in Figure 4, moreover, there was a significant correlation between urinary prostaticin and plasma aldosterone (correlation coefficient: 0.229;  $P<0.05$ ), whereas plasma cortisol levels did not show any significant correlation with urinary aldosterone levels (correlation coefficient: 0.152; not significant (NS)). In addition, urinary prostaticin excretion was inversely correlated with urinary Na/K ratio (correlation coefficient:  $-0.425$ ;  $P<0.0001$ ) (Figure 5), and urinary aldosterone



**Figure 4** Correlation between urinary prostaticin and plasma aldosterone levels. Correlation coefficient is 0.229 ( $P<0.05$ ).



**Figure 5** Correlation between prostaticin level and Na/K ratio in urine. Correlation coefficient is  $-0.425$  ( $P<0.0001$ ).

level had a significant negative correlation with urinary Na/K ratio (correlation coefficient:  $-0.445$ ;  $P<0.0001$ ). We also analyzed the relationships between urinary prostaticin and urinary albumin, systolic BP or diastolic BP. However, we did not see any significant correlation within these parameters (correlation coefficient: 0.140, 0.028 and 0.010, respectively; NS). The ratio of plasma aldosterone to renin activity,<sup>34</sup> a useful screening test for the diagnosis of primary aldosteronism, was not correlated with urinary prostaticin (correlation coefficient: 0.022; NS). Furthermore, renal function that is estimated by the eGFR formula had no effect on either urinary prostaticin or urinary aldosterone levels (correlation coefficient: 0.044 and 0.040, respectively; NS).

## DISCUSSION

This study is the first report of a clinical investigation using an RIA for human prostaticin to directly assess urinary prostaticin and to determine the relationship between prostaticin and aldosterone levels. To date, prostaticin has been detected using techniques such as immunohistochemistry and immunoblotting. More recently, Olivieri *et al.*<sup>20</sup> established urinary prostaticin as a possible candidate marker of ENaC activation using two-dimensional immunoblotting. The RIA that we developed for the measurement of human prostaticin using a partial

peptide synthesized according to the amino-acid sequence of human prostaticin and a recombinant prostaticin expressed in silkworm as a radioligand and a reference standard, respectively, was shown to be specific enough to measure urinary prostaticin levels. Parallelism of inhibition curves between the recombinant prostaticin standard and body fluids such as seminal fluid and urine indicates that the intact form of human prostaticin is measurable with this RIA. However, a large amount of prostaticin standard was necessary for the displacement of radioligand from the antiserum, suggesting the relatively lower sensitivity of this RIA. Yu *et al.*<sup>10</sup> produced an antiserum against prostaticin purified from human seminal fluid to develop an RIA for human prostaticin. The value of urinary prostaticin that we obtained in the present experiment was quite comparable with their value. When the same volume of urine that we used for the RIA was subjected to SDS-polyacrylamide gel electrophoresis and immunoblotting, each level of prostaticin estimated with the RIA was reflected in the level of intensity of the prostaticin band immunoreacted with monoclonal antibody against human prostaticin.

First of all, we analyzed the relationship between prostaticin and BP to identify a potential candidate for a novel marker for the pathogenesis of hypertension. In this study, however, we were unable to find an association between BP and prostaticin within these samples (data not shown). The reason for this may be derived from the constantly normalized value of BP to less than 140/90 mm Hg (systolic BP/diastolic BP;  $138.9 \pm 2.3/80.9 \pm 1.3$  mm Hg) in most of the patients, by virtue of treatment with antihypertensive medications. Antihypertensive drugs, such as Ca channel blockers, may have a direct effect on urinary prostaticin levels. Moreover, many of the subjects in this study had multiple complications including diabetes, renal failure and obesity. These metabolic factors may also have an impact on urinary prostaticin levels. However, as our study size was not large enough, we were unable to analyze the influence of those drugs or complications on the urinary prostaticin level.

We found that urinary prostaticin had a highly significant positive correlation with urinary aldosterone levels using the RIA system. A significant positive correlation was also shown between urinary prostaticin and plasma aldosterone. To our knowledge, this is the first report showing that an increase in urinary prostaticin excretion is concomitant with an increase in urinary or plasma aldosterone. We previously showed the stimulatory effect of aldosterone on the substantial increase in prostaticin gene expression and on the accumulation of prostaticin in the culture medium of cortical collecting duct cells or urine in the rat, with functional consequences on sodium balance *in vivo*.<sup>19</sup> To elucidate the source of the urinary excreted prostaticin, we determined the relationship between urinary albumin and urinary prostaticin. As described above, we did not detect any significant correlation between them. Therefore, we speculated that major part of the urinary prostaticin was produced and secreted by the renal tubules. We also previously showed that urinary excretion of prostaticin is increased in aldosterone-infused rat and in patients with primary aldosteronism, and that adrenalectomy in these patients significantly reduces urinary prostaticin excretion. Recently, Olivieri *et al.*<sup>20</sup> showed that there exists an aldosterone-responsive aliquot in urinary prostaticin that is modulated by sodium intake and is potentially suitable as a candidate marker of ENaC activation. Our present data showing a significant negative correlation (correlation coefficient:  $-0.425$ ,  $P < 0.0001$ ) between Na/K ratio and prostaticin strongly support their observation. A negative correlation between urinary aldosterone level and urinary Na/K ratio suggest the cooperative relationship among aldosterone, prostaticin and ENaC. Taken together, these findings indicate that prostaticin is an important physiological

regulator of sodium handling in the kidney, and that aldosterone plays a regulatory role in prostaticin expression and urinary sodium and potassium balance. The RIA for urinary prostaticin developed by us will be a useful tool for the non-invasive evaluation of ENaC activity in the kidney. As an increased ENaC activity is involved in some case of salt-sensitive hypertension, the measurement of urinary prostaticin levels by this RIA may serve as a diagnostic tool for the salt-sensitive hypertension and for choosing an appropriate therapeutic strategy for hypertension.

In conclusion, we detected prostaticin in urine from normotensive and hypertensive subjects by using an RIA for prostaticin developed by us. This is the first study to show a link between urinary prostaticin and urine or plasma aldosterone in humans. A concomitant increase in urinary prostaticin and a decrease in urinary Na/K ratio confirm previous findings. Our findings suggest that urinary prostaticin may serve as a surrogate marker for ENaC activation that leads to hypertension. However, it is not clear, at the present time, whether endogenous aldosterone regulates prostaticin expression or vice versa. Further study will be required to elucidate this.

#### ACKNOWLEDGEMENTS

We thank Drs Hiroyuki Fujisaki (Hirasa Clinic), Shigeru Kiyama (Kiyama-Nakamura Clinic), Yoshinori Ko (Ko Clinic), Takehiro Ko, Shiho Wakamatsu and Masataka Adachi (Kumamoto University) for sample collection. This work was supported by the following: Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan (19590956 to KK and 18390252 to KT); Salt Science Research Foundation Grant (0728 to KK); Mitsubishi Pharma Research Foundation Grant (to KK); and Suzuken Memorial Foundation Grant (to KK).

- Barby P, Lazdunski M. Structure and regulation of the amiloride-sensitive epithelial sodium channel. *Ion Channels* 1996; **4**: 115–167.
- Funder JW. Aldosterone action. *Annu Rev Physiol* 1993; **55**: 115–130.
- Garty H, Palmer LG. Epithelial sodium channels: function, structure, and regulation. *Physiol Rev* 1997; **77**: 359–396.
- Rossier BC. 1996 Homer smith award lecture. Cum grano salis: the epithelial sodium channel and the control of blood pressure. *J Am Soc Nephrol* 1997; **8**: 980–992.
- Verrey F. Early aldosterone action: toward filling the gap between transcription and transport. *Am J Physiol* 1999; **277** (3 Part 2): F319–F327.
- Canessa CM, Schild L, Buehl G, Thorens B, Gautschi I, Horisberger JD, Rossier BC. Amiloride-sensitive epithelial Na<sup>+</sup> channel is made of three homologous subunits. *Nature* 1994; **367**: 463–467.
- Canessa CM, Horisberger JD, Rossier BC. Epithelial sodium channel related to proteins involved in neurodegeneration. *Nature* 1993; **361**: 467–470.
- Vallet V, Chraïbi A, Gaeggeler HP, Horisberger JD, Rossier BC. An epithelial serine protease activates the amiloride-sensitive sodium channel. *Nature* 1997; **389**: 607–610.
- Vuagniaux G, Vallet V, Jaeger NF, Pfister C, Bens M, Farman N, Courtois-Couty N, Vandewalle A, Rossier BC, Hummler E. Activation of the amiloride-sensitive epithelial sodium channel by the serine protease mCAP1 expressed in a mouse cortical collecting duct cell line. *J Am Soc Nephrol* 2000; **11**: 828–834.
- Yu JX, Chao L, Chao J. Prostaticin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. *J Biol Chem* 1994; **269**: 18843–18848.
- Yu JX, Chao L, Ward DC, Chao J. Structure and chromosomal localization of the human prostaticin (PRSS8) gene. *Genomics* 1996; **32**: 334–340.
- Yu JX, Chao L, Chao J. Molecular cloning, tissue-specific expression, and cellular localization of human prostaticin mRNA. *J Biol Chem* 1995; **270**: 13483–13489.
- Chen LM, Skinner ML, Kauffman SW, Chao J, Chao L, Thaler CD, Chai KX. Prostaticin is a glycosylphosphatidylinositol-anchored active serine protease. *J Biol Chem* 2001; **276**: 21434–21442.
- Chen LM, Hodge GB, Guarda LA, Welch JL, Greenberg NM, Chai KX. Down-regulation of prostaticin serine protease: a potential invasion suppressor in prostate cancer. *Prostate* 2001; **48**: 93–103.
- Chen LM, Wang C, Chen M, Marcello MR, Chao J, Chao L, Chai KX. Prostaticin attenuates inducible nitric oxide synthase expression in lipopolysaccharide-induced urinary bladder inflammation. *Am J Physiol Renal Physiol* 2006; **291**: F567–F577.

- 16 Lin HY, Zhang H, Yang Q, Wang HX, Wang HM, Chai KX, Chen LM, Zhu C. Expression of prostaticin and protease Nexin-1 in rhesus monkey (*Macaca mulatta*) endometrium and placenta during early pregnancy. *J Histochem Cytochem* 2006; **54**: 1139–1147.
- 17 Donaldson SH, Hirsh A, Li DC, Holloway G, Chao J, Boucher RC, Gabriel SE. Regulation of the epithelial sodium channel by serine proteases in human airways. *J Biol Chem* 2002; **277**: 8338–8345.
- 18 Iwashita K, Kitamura K, Narikiyo T, Adachi M, Shiraishi N, Miyoshi T, Nagano J, Tuyen dG, Nonoguchi H, Tomita K. Inhibition of prostaticin secretion by serine protease inhibitors in the kidney. *J Am Soc Nephrol* 2003; **14**: 11–16.
- 19 Narikiyo T, Kitamura K, Adachi M, Miyoshi T, Iwashita K, Shiraishi N, Nonoguchi H, Chen LM, Chai KX, Chao J, Tomita K. Regulation of prostaticin by aldosterone in the kidney. *J Clin Invest* 2002; **109**: 401–408.
- 20 Olivieri O, Castagna A, Guarini P, Chiecchi L, Sabaini G, Pizzolo F, Corrocher R, Righetti PG. Urinary prostaticin: a candidate marker of epithelial sodium channel activation in humans. *Hypertension* 2005; **46**: 683–688.
- 21 Rossier BC. The epithelial sodium channel: activation by membrane-bound serine proteases. *Proc Am Thorac Soc* 2004; **1**: 4–9.
- 22 Tong Z, Illek B, Bhagwandin VJ, Verghese GM, Caughey GH. Prostaticin, a membrane-anchored serine peptidase, regulates sodium currents in JME/CF15 cells, a cystic fibrosis airway epithelial cell line. *Am J Physiol Lung Cell Mol Physiol* 2004; **287**: L928–L935.
- 23 Tuyen DG, Kitamura K, Adachi M, Miyoshi T, Wakida N, Nagano J, Nonoguchi H, Tomita K. Inhibition of prostaticin expression by TGF- $\beta$ 1 in renal epithelial cells. *Kidney Int* 2005; **67**: 193–200.
- 24 Chen LM, Chai KX. Prostaticin serine protease inhibits breast cancer invasiveness and is transcriptionally regulated by promoter DNA methylation. *Int J Cancer* 2002; **97**: 323–329.
- 25 Chen LM, Zhang X, Chai KX. Regulation of prostaticin expression and function in the prostate. *Prostate* 2004; **59**: 1–12.
- 26 Takahashi S, Suzuki S, Inaguma S, Ikeda Y, Cho YM, Hayashi N, Inoue T, Sugimura Y, Nishiyama N, Fujita T, Chao J, Ushijima T, Shirai T. Down-regulated expression of prostaticin in high-grade or hormone-refractory human prostate cancers. *Prostate* 2003; **54**: 187–193.
- 27 Adachi M, Kitamura K, Miyoshi T, Narikiyo T, Iwashita K, Shiraishi N, Nonoguchi H, Tomita K. Activation of epithelial sodium channels by prostaticin in *Xenopus* oocytes. *J Am Soc Nephrol* 2001; **12**: 1114–1121.
- 28 Wang C, Chao J, Chao L. Adenovirus-mediated human prostaticin gene delivery is linked to increased aldosterone production and hypertension in rats. *Am J Physiol Regul Integr Comp Physiol* 2003; **284**: R1031–R1036.
- 29 Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. *Proc Natl Acad Sci* 1988; **85**: 5409–5413.
- 30 Goudie RB, Horne CH, Wilkinson PC. A simple method for producing antibody specific to a single selected diffusible antigen. *Lancet* 1966; **2**: 1224–1226.
- 31 Yamamoto K, Toyoda F, Tanaka S, Hayashi H, Kikuyama S. Radioimmunoassay of a new sex pheromone, sodefrin, and the influence of hormones on its level in the abdominal gland. *Gen Comp Endocrinol* 1996; **104**: 356–363.
- 32 Bliss CI. *Statistics in Biology*. McGraw-Hill: New York, 1967.
- 33 Snedecor GW, Cochran WG. *Statistical Methods Applied to Experiments in Agriculture and Biology*, 7th edn. Iowa State University Press: Ames, 1980.
- 34 Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. *Hypertens Res* 2007; **30**: 111–117.